Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

FDA Defends Stance on Biosimilar Product Labeling

The agency is trying to avoid any "potential confusion."

The FDA recently posted a message, written by Dr. Christl, the Associate Director for Therapeutic Biologics in the Office of New Drugs at the agency's Center for Drug Evaluation and Research, explaining their stance on biosimilar labeling.

Titled "From our perspetive," the message explains that although there is "a lot of work to do," the agency thinks, "that our approach to biosimilar labeling will be truly beneficial to health care providers as they consider prescribing options and the risk-benefit decisions for their patients."

Christl explains that the agency has taken an "approach to avoid potential confusion or misinterpretation of the comparative data."

"While we recommend that biosimilar labeling include biosimilar product-specific data necessary to inform safe and effective use of the product, we generally do not recommend that comparative data supporting the demonstration of biosimilarity be included in biosimilar product labeling," she writes.

Medical Device Innovations Report
Cutting-edge packaging technologies are transforming the medical device sector in PMMI’s “Innovation in Medical Device” report, featuring advanced materials, smart solutions, and evolving regulations. Editors share insights from nearly 300 PACK EXPO booth visits—each product deemed new and truly innovative—alongside video demonstrations of the equipment and materials on display.
Learn More
Medical Device Innovations Report
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?